Drug Combination Improves Parkinson's Symptoms in Mice
Researchers test a new drug cocktail that stabilizes oxygen delivery to help address mitochondrial dysfunction in mice.
Updated on Oct. 22, 2026 in Alzheimer’s
Live Poll
Are you confident that new medical discoveries in animal models will lead to human cures?
Scientists have successfully used a drug combination consisting of GBT601 and PT2399 to improve motor performance in mice exhibiting symptoms similar to Parkinson's disease. The treatment aims to correct oxygen imbalances caused by mitochondrial dysfunction.
Why it matters
This study addresses the critical issue of oxygen delivery mismatches in the brain, offering a potential new strategy for neurodegenerative conditions. While promising, the researchers emphasized that the concept requires significant additional testing before it can be considered for human clinical trials.
In a Leigh syndrome mouse model, the treatment extended median lifespan to 158 days from a baseline of 62 days. The research team also monitored for pulmonary hypertension, observing no increase in heart measurements after six weeks of treatment.
The players
Harvard Medical School
This institution served as the base for the lead researchers who conducted the study on mitochondrial dysfunction.
The details
The treatment works by modulating oxygen delivery through GBT601, which reduces oxygen release into tissues, and PT2399, which limits red blood cell production. Treated mice showed improved results on pole and cage-hang tests, though the combination did not alleviate anxiety-like behaviors in the animal subjects.
Timeline
Treatment began six weeks after researchers injected alpha-synuclein fibrils into the mice.
Mice showed improved movement after six weeks of daily oral administration.
Researchers conducted a study on continuous low-oxygen breathing in 2025.
The Big Picture
This discovery follows the path set by Harvard Medical School's mitochondrial dysfunction research programs to address neurological decay. It marks a significant shift in experimental approaches by prioritizing oxygen regulation as a means to mitigate tissue damage in neurodegenerative models.
This study is a preliminary investigation in mice and does not change current treatment options for patients living with Parkinson's disease. Future clinical research will be necessary to determine if this oxygen-modulating approach can eventually lead to safe human therapies.
The takeaway
This study highlights the importance of managing mitochondrial oxygen delivery in neurodegenerative disease models. While the results in mice are encouraging, further research is required to evaluate the safety and clinical applicability of these compounds in humans.
Further reading
Learn more about the latest research into neurodegenerative conditions by visiting the Alzheimer’s section.
Source note: This article includes information reported by ScienceAlert.
Live Poll
Are you confident that new medical discoveries in animal models will lead to human cures?
